- Email: [email protected]
ABC1 – Disclosure of conflict of interest
The Breast 20 (2011) S56–S57
Contents lists available at ScienceDirect
The Breast journal homepage: www.elsevier.com/brst
ABC1 – Disclosure of conflict of interest
Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above mentioned event. Potential conflict of interest are considered any of the following: Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the consensus process. Any financial interest in or arrangement with a competing company. Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the consensus process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition. ABC1 chairs, faculty and panel members Matti Aapro: Abraxis, Amgen, AstraZeneca, Bayer Schering, Bristol Myers, Celgene, Cephalon, GSK, Helsinn, Hospira, Johnson and Johnson, Ortho Biotech, Merck, MSD, Novartis, Pfizer, PierreFabre, Roche, Sandoz, Schering, Sanofi-Aventis, Vifor: speakers bureau, consultant, research support. Jonas Bergh: Affibodies, Amgen, AstraZeneca, 13 Innovus, GSK, Onyx, Pfizer, Sanofi-Aventis, Tapestry: consultant or advisory role. All payments made to Asklepios Medicine (none to Prof. J. Bergh). Sanofi-Aventis, Amgen, Merck: research support. All payments made to Karolinska University Hospital (none to Prof. J. Bergh). Bettina Borisch: No significant relationships. Jacqueline F. Bromberg: No significant relationships. David A. Cameron: Roche, GSK, Pfizer: consultant or advisory board member and travel support. Roche: speakers bureau and research support. Pfizer: research support. Sanofi-Aventis: consultant or advisory board member. Amgen: research support and consultant. Fatima Cardoso: GSK: speakers bureau, consultant, travel support. Roche: speakers bureau, consultant, research support, travel support. Eisai: speakers bureau, consultant, travel support. Pfizer: speakers bureau, consultant, travel support. Novartis: speakers bureau, consultant, research support, travel support. AstraZeneca: speakers bureau, consultant, research support, travel support. Johnson and Johnson: consultant, research support, travel support. Sanofi-Aventis: speakers bureau, consultant, travel support. Wilex: consultant. Bristol-MyersSquibb: consultant, travel support. Abraxis/Celgene: consultant. 0960-9776/$ – see front matter doi:10.1016/j.breast.2011.08.130
Robert E. Coleman: Novartis: speakers bureau, consultant. Amgen: speakers bureau, consultant. Alberto Costa: No significant relationships. Tanja Cufer: No significant relationships. Pier Paolo Di Fiore: No significant relationships. Angelo Di Leo: AstraZeneca, GSK, Pfizer, Roche, Sanofi-Aventisi, Cephalon: consultant, honoraria. AstraZeneca, GSK: research support. Nagi El Saghir: As Lecturer: no significant relationships. As Panellist: Roche, GSK: speakers bureau, research support, travel support. Novartis: research support, travel support. Sanofi-Aventis: research support. Lesley Fallowfield: No significant relationships. Prudence Francis: Amgen, Sanofi-Aventis: travel support. Roche: honorarium. Patricia Ganz: No significant relationships. Karen Gelmon: Roche: consultant. GSK: research support: AstraZeneca: consultant. Amgen: consultant. Joseph Gligorov: Roche, Sanofi-Aventis and Eisai: Consultant or advisory board member. Roche and Novartis: Research support. Novartis: speaker’s bureau. Aron Goldhirsch: Novartis, GSK: speakers bureau. Pfizer: travel support. Roger Gomis: No significant relationships. Nadia Harbeck: Roche: speakers bureau, consultant, research support. Sanofi-Aventis: speakers bureau, consultant. Amgen, Novartis, GSK: speakers bureau. AstraZeneca, Eisai: consultant. Nehmat Houssami: No significant relationships. Clifford A. Hudis: Onyx, Bayer: research support. Stephen Johnston: GlaxoSmithKline and Roche: Consultant or advisory board member. AstraZeneca and Roche: Research support. Bella Kaufman: Roche: speakers bureau, GSK: Consultant or advisory board member, Janssen-Cilag: Travel support. Ian E. Krop: Genentech/Roche: Research support, Novartis: Consultant or advisory board member, Stella Kyriakides: No significant relationships. Maria Leadbeater: No significant relationships. Nancy U. Lin: Genentech, GSK, Boehringer Ingelheim, Bayer: research support. David C. Lyden: No significant relationships. Musa Mayer: No significant relationships. Larry Norton: No significant relationships. Olivia Pagani: No significant relationships. Kathy Redmond: Novartis: consultant. Amgen: consultant. GSK: consultant. Alan Rodger: No significant relationships.
ABC1 – Disclosure of conflict of interest / The Breast 20 (2011) S56–S57
Hope S. Rugo: Genomic: consultant. Genentech/Roche, Merck, Novartis, BMS, Celgene, Sanofi/Bipar, Lilly/Imclone: research support to UCSF. Virgilio Sacchini: No significant relationships. Elzbieta Senkus-Konefka: Roche: travel support. Glaxo SmithKline: speakers bureau, travel support. AstraZeneca: speakers bureau. Sanofi Aventis: speakers bureau, travel support. Pfizer: travel support. George W. Sledge: No significant relationships. Christoph Thomssen: Amgen, Astra-Zeneca and Pfizer: speakers bureau, consultant or advisory board member, travel support. Celgene: consultant or advisory board member and travel
S57
support. Eisai: consultant or advisory board member. Glaxo (GSK), Roche: speakers bureau and consultant or advisory board member. Novartis, Sanofi: speakers bureau, consultant or advisory board member and research support. Andrew Tutt: Sanofi-Aventis: consultant, research support, travel support. AstraZeneca: consultant, research support, travel support. Clovis: consultant. Eisai: consultant. Laura van’t Veer: Agendia NV: Stock royalty or equity ownership and employment. Giuseppe Viale: No significant relationships. Eric P. Winer: Novartis: honorarium for one meeting. Zhang Xhiang: No significant relationships.
Contents lists available at ScienceDirect
The Breast journal homepage: www.elsevier.com/brst
ABC1 – Disclosure of conflict of interest
Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the above mentioned event. Potential conflict of interest are considered any of the following: Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the consensus process. Any financial interest in or arrangement with a competing company. Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the consensus process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition. ABC1 chairs, faculty and panel members Matti Aapro: Abraxis, Amgen, AstraZeneca, Bayer Schering, Bristol Myers, Celgene, Cephalon, GSK, Helsinn, Hospira, Johnson and Johnson, Ortho Biotech, Merck, MSD, Novartis, Pfizer, PierreFabre, Roche, Sandoz, Schering, Sanofi-Aventis, Vifor: speakers bureau, consultant, research support. Jonas Bergh: Affibodies, Amgen, AstraZeneca, 13 Innovus, GSK, Onyx, Pfizer, Sanofi-Aventis, Tapestry: consultant or advisory role. All payments made to Asklepios Medicine (none to Prof. J. Bergh). Sanofi-Aventis, Amgen, Merck: research support. All payments made to Karolinska University Hospital (none to Prof. J. Bergh). Bettina Borisch: No significant relationships. Jacqueline F. Bromberg: No significant relationships. David A. Cameron: Roche, GSK, Pfizer: consultant or advisory board member and travel support. Roche: speakers bureau and research support. Pfizer: research support. Sanofi-Aventis: consultant or advisory board member. Amgen: research support and consultant. Fatima Cardoso: GSK: speakers bureau, consultant, travel support. Roche: speakers bureau, consultant, research support, travel support. Eisai: speakers bureau, consultant, travel support. Pfizer: speakers bureau, consultant, travel support. Novartis: speakers bureau, consultant, research support, travel support. AstraZeneca: speakers bureau, consultant, research support, travel support. Johnson and Johnson: consultant, research support, travel support. Sanofi-Aventis: speakers bureau, consultant, travel support. Wilex: consultant. Bristol-MyersSquibb: consultant, travel support. Abraxis/Celgene: consultant. 0960-9776/$ – see front matter doi:10.1016/j.breast.2011.08.130
Robert E. Coleman: Novartis: speakers bureau, consultant. Amgen: speakers bureau, consultant. Alberto Costa: No significant relationships. Tanja Cufer: No significant relationships. Pier Paolo Di Fiore: No significant relationships. Angelo Di Leo: AstraZeneca, GSK, Pfizer, Roche, Sanofi-Aventisi, Cephalon: consultant, honoraria. AstraZeneca, GSK: research support. Nagi El Saghir: As Lecturer: no significant relationships. As Panellist: Roche, GSK: speakers bureau, research support, travel support. Novartis: research support, travel support. Sanofi-Aventis: research support. Lesley Fallowfield: No significant relationships. Prudence Francis: Amgen, Sanofi-Aventis: travel support. Roche: honorarium. Patricia Ganz: No significant relationships. Karen Gelmon: Roche: consultant. GSK: research support: AstraZeneca: consultant. Amgen: consultant. Joseph Gligorov: Roche, Sanofi-Aventis and Eisai: Consultant or advisory board member. Roche and Novartis: Research support. Novartis: speaker’s bureau. Aron Goldhirsch: Novartis, GSK: speakers bureau. Pfizer: travel support. Roger Gomis: No significant relationships. Nadia Harbeck: Roche: speakers bureau, consultant, research support. Sanofi-Aventis: speakers bureau, consultant. Amgen, Novartis, GSK: speakers bureau. AstraZeneca, Eisai: consultant. Nehmat Houssami: No significant relationships. Clifford A. Hudis: Onyx, Bayer: research support. Stephen Johnston: GlaxoSmithKline and Roche: Consultant or advisory board member. AstraZeneca and Roche: Research support. Bella Kaufman: Roche: speakers bureau, GSK: Consultant or advisory board member, Janssen-Cilag: Travel support. Ian E. Krop: Genentech/Roche: Research support, Novartis: Consultant or advisory board member, Stella Kyriakides: No significant relationships. Maria Leadbeater: No significant relationships. Nancy U. Lin: Genentech, GSK, Boehringer Ingelheim, Bayer: research support. David C. Lyden: No significant relationships. Musa Mayer: No significant relationships. Larry Norton: No significant relationships. Olivia Pagani: No significant relationships. Kathy Redmond: Novartis: consultant. Amgen: consultant. GSK: consultant. Alan Rodger: No significant relationships.
ABC1 – Disclosure of conflict of interest / The Breast 20 (2011) S56–S57
Hope S. Rugo: Genomic: consultant. Genentech/Roche, Merck, Novartis, BMS, Celgene, Sanofi/Bipar, Lilly/Imclone: research support to UCSF. Virgilio Sacchini: No significant relationships. Elzbieta Senkus-Konefka: Roche: travel support. Glaxo SmithKline: speakers bureau, travel support. AstraZeneca: speakers bureau. Sanofi Aventis: speakers bureau, travel support. Pfizer: travel support. George W. Sledge: No significant relationships. Christoph Thomssen: Amgen, Astra-Zeneca and Pfizer: speakers bureau, consultant or advisory board member, travel support. Celgene: consultant or advisory board member and travel
S57
support. Eisai: consultant or advisory board member. Glaxo (GSK), Roche: speakers bureau and consultant or advisory board member. Novartis, Sanofi: speakers bureau, consultant or advisory board member and research support. Andrew Tutt: Sanofi-Aventis: consultant, research support, travel support. AstraZeneca: consultant, research support, travel support. Clovis: consultant. Eisai: consultant. Laura van’t Veer: Agendia NV: Stock royalty or equity ownership and employment. Giuseppe Viale: No significant relationships. Eric P. Winer: Novartis: honorarium for one meeting. Zhang Xhiang: No significant relationships.